Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis

JAMA Neurology

Volumn 72, Issue 4, 2015, Pages 405-413

  He, Anna ^a   Spelman, Tim ^b   Jokubaitis, Vilija ^b   Havrdova, Eva ^c,d   Horakova, Dana ^c,d   Trojano, Maria ^e   Lugaresi, Alessandra ^f   Izquierdo, Guillermo ^g   Grammond, Pierre ^h   Duquette, Pierre ⁱ   Girard, Marc ⁱ   Pucci, Eugenio ^j   Iuliano, Gerardo ^k   Alroughani, Raed ^l   Oreja Guevara, Celia ^m   Fernandez Bolaños, Ricardo ⁿ   Grand'Maison, Francois ^o   Sola, Patrizia ^p   Spitaleri, Daniele ^q   Granella, Franco ^r   Terzi, Murat ^s   Lechner Scott, Jeannette ^t,u   Van Pesch, Vincent ^v   Hupperts, Raymond ^w   Sánchez Menoyo, José Luis ^x   Hodgkinson, Suzanne ^y   Rozsa, Csilla ^z   Verheul, Freek ^aa   Butzkueven, Helmut ^a,b,ab   Kalincik, Tomas ^a,b   Giuliani, G ^ac   Cartechini, E ^ac   Rio, M E ^ac   Zwanikken, C ^ac   Flechter, S ^ac   Kasa, K ^ac   Amato, M P ^ac   Shaygannejad, V ^ac   Bergamaschi, R ^ac   Slee, M ^ac   Boz, C ^ac   Moore, F ^ac   Barnett, M ^ac   Vucic, S ^ac   McCombe, P ^ac   Cabrera Gomez, J A ^ac   Petersen, T ^ac   Ramo, C ^ac   Roullet, E ^ac   Den Braber Moerland, L ^ac   Paolicelli, D ^ac   Iaffaldano, P ^ac   Direnzo, V ^ac   D'Onghia, M ^ac   Piroska, I ^ac   Erdelyi, T ^ac   Iljicsov, A ^ac   Kovacs, K ^ac   Sas, A ^ac   Skibina, O ^ac   Haartsen, J ^ac   van Munster, E ^ac   Fiol, M ^ac   Correale, J ^ac   Ysrraelit, C ^ac   Herbert, J ^ac   Kister, I ^ac   Sirbu, C A ^ac   Shaw, C ^ac   Vetere, S ^ac   Petkovska Boskova, T ^ac   Singhal, B ^ac   Bacile, E A ^ac   Arruda, W O ^ac   Roger, E ^ac   Despault, P ^ac   Marriott, M ^ac   Van der Walt, A ^ac   King, J ^ac   Byron, J ^ac   Morgan, L ^ac   Hinson, E ^ac   De Luca, Giovanna ^ac   Di Tommaso, V ^ac   Travaglini, D ^ac   Pietrolongo, E ^ac   di Ioia, M ^ac   Farina, D ^ac   Mancinelli, L ^ac   Rojas, J I ^ac   Patrucco, L ^ac   Williams, D ^ac   Dark, L ^ac   Savino, A ^ac   Chapman, J ^ac   Cristiano, E ^ac   Saladino, M L ^ac   Deri, N ^ac   Gray, O ^ac   Hughes, S ^ac   Paine, M ^ac   Vella, N ^ac   Mechati, S ^ac   Corageoud, M ^ac   Bulla, A ^ac   more..

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c CHARLES UNIVERSITY   (Czech Republic)

^d CHARLES UNIVERSITY   (Czech Republic)

^e UNIVERSITY OF BARI   (Italy)

^f UNIVERSITY OF CHIETI   (Italy)

^g HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^h Hotel Dieu de Levis Hospital   (Canada)

ⁱ NOTRE DAME HOSPITAL   (Canada)

^j ASUR Marche   (Italy)

^k Ospedali Riuniti di Salerno   (Italy)

^l AL AMIRI HOSPITAL   (Kuwait)

^m HOSPITAL CLÍNICO SAN CARLOS   (Spain)

ⁿ HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^o HÔPITAL CHARLES LEMOYNE   (Canada)

^p Dipartimento di Emergenza e Urgenza   (Italy)

^q Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati   (Italy)

^r UNIVERSITY OF PARMA   (Italy)

^s ONDOKUZ MAYIS UNIVERSITY   (Turkey)

^t JOHN HUNTER HOSPITAL   (Australia)

^u UNIVERSITY OF NEWCASTLE   (Australia)

^v CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^w Zuyderland Medical Centre   (Netherlands)

^x HOSPITAL DE GALDAKAO   (Spain)

^y LIVERPOOL HOSPITAL   (Australia)

^z Jahn Ferenc Del Pesti korhaz Budapest   (Hungary)

^aa Groen Hart Ziekenhuis   (Netherlands)

^ab MONASH UNIVERSITY   (Australia)

^ac NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; FINGOLIMOD; GLATIRAMER; INTERFERON BETA SERINE; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

ADULT; ARTICLE; AUSTRALIA; CANADA; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; CZECH REPUBLIC; DISABILITY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; HAZARD RATIO; HUMAN; IMMUNOMODULATION; ITALY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NETHERLANDS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPENSITY SCORE; RELAPSE; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SPAIN; TREATMENT DURATION; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PROCEDURES; TREATMENT OUTCOME;

ADULT; COHORT STUDIES; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS; PROPYLENE GLYCOLS; RETROSPECTIVE STUDIES; SPHINGOSINE; TREATMENT OUTCOME;

EID: 84928169402     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.4147     Document Type: Article

References (33)

1. Brinkmann V, DavisMD, Heise CE, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002;277(24):21453-21457.
2. Kappos L, Antel J, Comi G, et al; FTY720 D2201 Study Group. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006;355(11):1124-1140.
3. O'Connor P, Comi G, Montalban X, et al; FTY720 D2201 Study Group. Oral fingolimod (FTY720) in multiple sclerosis. Neurology. 2009;72(1):73-79.
4. Montalban X, Comi G, O'Connor P, et al. Oral fingolimod (FTY720) in relapsing multiple sclerosis. Mult Scler. 2011;17(11):1341-1350.
5. Comi G, O'Connor P, Montalban X, et al; FTY720D2201 Study Group. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler. 2010;16(2):197-207.
6. Fazekas F, Bajenaru O, Berger T, et al. How does fingolimod (Gilenya®) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis? Front Neurol. 2013;4:10.
7. Fazekas F, Berger T, Fabjan TH, et al. Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group. Wien Med Wochenschr. 2012;162(15-16):354-366.
8. Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(6):545-556.
9. Kappos L, Radue EW, O'Connor P, et al FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387-401.
10. Cohen JA, Barkhof F, Comi G, et al TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402-415.
11. Panitch H, Goodin DS, Francis G, et al EVIDENCE Study Group; Evidence of Interferon Dose-Response: European North American Comparative Efficacy; University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial. Neurology. 2002;59(10):1496-1506.
12. Lublin FD, Cofield SS, Cutter GR, et al; CombiRx Investigators. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol. 2013;73(3):327-340.
13. Butzkueven H, Chapman J, Cristiano E, et al. MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. Mult Scler. 2006;12(6):769-774.
14. Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Di Renzo V. observational studies: propensity score analysis of non-randomized data. Int MS J. 2009;16(3):90-97.
15. Kalincik T, Spelman T, Trojano M, et al MSBase Study Group. Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis. PLoS One. 2013;8(5):e63480. doi:10.1371/journal.pone.0063480.
16. Goodin DS, Jones J, Li D, et al; 16-Year Long-Term Follow-up Study Investigators. Establishing long-term efficacy in chronic disease. PLoS One. 2011;6(11):e22444. doi:10.1371/journal.pone.0022444.
17. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc. 1984;79(387):516-524.
18. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444-1452.
19. Ho DS, Imai K, King G, Stuart EA. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw. 2011;42(8):1-28.
20. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2011.
21. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis. Ann Neurol. 2011;69(2):292-302.
22. Schoenfeld D. Chi-squared goodness-of-fit tests for the proportional hazards regression model. Biometrika. 1980;67(1):145-153.
23. nd ed. New York, NY: Springer-Verlag; 2002.
24. Khatri B, Barkhof F, Comi G, et al TRANSFORMS Study Group. Comparison of fingolimod with interferon beta-1a in relapsing-remittingmultiple sclerosis. Lancet Neurol. 2011;10(6):520-529.
25. Cohen JA, Barkhof F, Comi G, et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. J Neurol. 2013;260 (8):2023-2032.
26. Bergvall N, Makin C, Lahoz R, et al. Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate. PLoS One. 2014;9(2):e88472.
27. Roskell NS, Zimovetz EA, Rycroft CE, Eckert BJ, Tyas DA. Annualized relapse rate of first-line treatments formultiple sclerosis. Curr Med Res Opin. 2012;28(5):767-780.
28. Del Santo F, Maratea D, Fadda V, Trippoli S, Messori A. Treatments for relapsing-remitting multiple sclerosis: summarising current information by networkmeta-analysis. Eur J Clin Pharmacol. 2012;68(4):441-448.
29. Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology. 2003;61(11):1528-1532.
30. Hirst C, IngramG, Pearson O, Pickersgill T, Scolding N, Robertson N. Contribution of relapses to disability in multiple sclerosis. J Neurol. 2008;255(2):280-287.
31. Filippini G, Del Giovane C, Vacchi L, et al. Immunomodulators and immunosuppressants for multiple sclerosis. Cochrane Database Syst Rev. 2013;6:CD008933. doi:10.1002/14651858.CD008933.pub2.
32. Kalincik T, Jokubaitis V, Izquierdo G, et al MSBase Study Group. Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis [published online December 5, 2014]. Mult Scler.
33. Kalincik T, Vivek V, Jokubaitis V, et al MSBase Study Group. Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. Brain. 2013;136(pt 12):3609-3617.